In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Firms like Moderna that are rapidly adopting AI and will have a higher mix of AI software robots to humans in the future ...

Moderna 57, a new Italian restaurant next to the Syosset train station, offers over 100 dishes to diners. The owner, Paul ...

Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Sioux City put a damper on Cleburne’s series-winning streak as the Railroaders dropped all three games to the Explorers over ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...